Curcuminoid supplementation alters proteomic profiles and clinical outcomes in canine primary epilepsy: A pilot study
- 1Department of Pre-Clinic and Applied Animal Science, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand
- 2Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand
- 3Department of Clinical Sciences and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand
Abstract
Background
In dogs, primary epilepsy syndrome (PES) requires lifelong pharmacological management. Curcuminoids possess anti-inflammatory and antioxidant properties with potential neuroprotective effects. This pilot study preliminarily evaluated the clinical efficacy and molecular mechanisms of curcuminoid supplementation in canine PES.Methods
In this prospective, open-label pilot study, eight dogs with PES on stable AED therapy received adjunctive oral curcuminoid supplementation (10-20 mg/kg/day) for 60 days. Clinical response, serum GSH/GSSG ratio (DTNB-glutathione reductase recycling assay), serum cytokine concentrations (ELISA), and global serum proteomic profiles (nano-LC-MS/MS) were assessed.Results
Clinical response, defined as a reduction in seizure frequency (3/8) or decreased severity (1/8) was observed in 4 of 8 dogs (50%). Curcuminoid supplementation significantly increased the GSH/GSSG ratio (P = 0.046) and induced distinct proteomic changes: downregulation of mammalian target of rapamycin (mTOR) pathway components (Ras-related GTP-binding protein C and regulatory-associated protein of mTOR) and Toll-like receptor 2 (TLR2) signaling and upregulation of one-carbon metabolism (methylenetetrahydrofolate dehydrogenase) and serine/glycine/threonine metabolism (phosphoserine aminotransferase 1) enzymes.Conclusion
Curcuminoid supplementation was safe, well tolerated, and demonstrated a clinical response rate of 50% in dogs with PES. These findings provide preliminary molecular evidence of enhanced antioxidant capacity, mTOR/TLR2 modulation, and metabolic reprogramming. As pilot observations, definitive neuroprotective conclusions require confirmation in larger controlled trials with direct neurological endpoints. Nonetheless, these data provide a molecular rationale for curcuminoids as adjunctive therapy in canine epilepsy.
Related
- Synbiotic HQP08 Supplementation for Hair Loss and Depressive Symptoms: An Open-Label Pilot Study of Clinical Outcomes and Gut Microbiome Changes
- Longitudinal analysis of clinical and biochemical outcomes during seven years of galactose supplementation in a patient with SLC35A2-CDG.
- Effects of synbiotic supplementation on clinical symptoms and metabolic outcomes in patients with painful diabetic neuropathy: a pilot randomized controlled trial.
- Vitamin D3 Supplementation Modulates C-MYC/VEGF and Improves Chemotherapy Outcomes in Metastatic CRC Patients: Integrated Clinical–Mechanistic Evidence
- Risk Factor Profiles and Clinical Outcomes: A 6-Month Longitudinal Study on Rehospitalization Rates in Patients with Chronic Heart Failure
BibTeX
@article{chantong2026curcuminoid,
title = {{Curcuminoid supplementation alters proteomic profiles and clinical outcomes in canine primary epilepsy: A pilot study}},
author = {Boonrat Chantong and Nutnicha Prakaikowit and Wanita Sangapol and Sirakarn Chatampaiwong and Sekkarin Ploypetch and Sataporn Phochantachinda and Duangthip Chatchaisak},
journal = {Veterinary and animal science},
year = {2026},
month = oct,
doi = {10.1016/j.vas.2026.100906},
url = {https://europepmc.org/article/PMC/PMC13718403},
note = {CC BY},
}
RIS
TY - JOUR
TI - Curcuminoid supplementation alters proteomic profiles and clinical outcomes in canine primary epilepsy: A pilot study
AU - Boonrat Chantong
AU - Nutnicha Prakaikowit
AU - Wanita Sangapol
AU - Sirakarn Chatampaiwong
AU - Sekkarin Ploypetch
AU - Sataporn Phochantachinda
AU - Duangthip Chatchaisak
PY - 2026
DA - 2026/10/20
JO - Veterinary and animal science
DO - 10.1016/j.vas.2026.100906
UR - https://europepmc.org/article/PMC/PMC13718403
AB - Background In dogs, primary epilepsy syndrome (PES) requires lifelong pharmacological management. Curcuminoids possess anti-inflammatory and antioxidant properties with potential neuroprotective effects. This pilot study preliminarily evaluated the clinical efficacy and molecular mechanisms of curcuminoid supplementation in canine PES.Methods In this prospective, open-label pilot study, eight dogs with PES on stable AED therapy received adjunctive oral curcuminoid supplementation (10-20 mg/kg/day) for 60 days. Clinical response, serum GSH/GSSG ratio (DTNB-glutathione reductase recycling assay), serum cytokine concentrations (ELISA), and global serum proteomic profiles (nano-LC-MS/MS) were assessed.Results Clinical response, defined as a reduction in seizure frequency (3/8) or decreased severity (1/8) was observed in 4 of 8 dogs (50%). Curcuminoid supplementation significantly increased the GSH/GSSG ratio (P = 0.046) and induced distinct proteomic changes: downregulation of mammalian target of rapamycin (mTOR) pathway components (Ras-related GTP-binding protein C and regulatory-associated protein of mTOR) and Toll-like receptor 2 (TLR2) signaling and upregulation of one-carbon metabolism (methylenetetrahydrofolate dehydrogenase) and serine/glycine/threonine metabolism (phosphoserine aminotransferase 1) enzymes.Conclusion Curcuminoid supplementation was safe, well tolerated, and demonstrated a clinical response rate of 50% in dogs with PES. These findings provide preliminary molecular evidence of enhanced antioxidant capacity, mTOR/TLR2 modulation, and metabolic reprogramming. As pilot observations, definitive neuroprotective conclusions require confirmation in larger controlled trials with direct neurological endpoints. Nonetheless, these data provide a molecular rationale for curcuminoids as adjunctive therapy in canine epilepsy.
SN - 2451-943X
ER -